Resources Repository
-
ArticlePublication 2022Vaccinations versus Lockdowns to Prevent COVID-19 Mortality
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly …
This analysis estimated the costs associated with preventing Covid-19 deaths by vaccinations versus lockdowns. Publicly available datasets from the Israeli Ministry of Health were used to model the parameters of the pandemic in Israel. The Oxford COVID-19 Government Response Tracker was used for quantitative data on government policies. Data on the Israeli economy were taken from the Central Bureau of Statistics. The models demonstrate that the first lockdown prevented 1022 COVID-19 deaths at the cost…
Costing Methods | Health Outcomes | Government/Law | Policy/Regulation | Infectious Diseases | Decision Theory | State-Transition | Decision Analysis | Economics/Finance | Health/Medicine | Middle East & North Africa -
ArticlePublication 2023Benefits and Costs of COVID-19 Vaccine Mandates
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations …
Written mid-pandemic, this article evaluates the direct costs and health benefits of requiring COVID-19 vaccinations for U.S. federal employees and healthcare and private sector workers. These mandates were controversial and some were halted by litigation. If they had been implemented as intended, the net benefits would depend on the course of the pandemic. If a more transmissible variant (such as Omicron) emerges, the net benefits may be large. If the pandemic instead fades, the benefits…
Benefit-Cost Analysis | Government/Law | Policy/Regulation | Infectious Diseases | Mathematical Models | State-Transition | Business/Industry | Economics/Finance | Health/Medicine | North America -
EditorialPublication 2020Waiting for Certainty on COVID-19 Antibody Tests — At What Cost?
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation …
This perspective anticipates the availability of serologic antibody testing and considers its potential usefulness in mitigation policy to reduce COVID-19 transmission. For example: Could we screen for serologic antibodies as a proxy for possible immunity and identify people who could return to the workplace with less severe mitigation measures? The authors acknowledge the uncertainties raised by many policy actors, including the WHO, such as, "Do antibodies confer immunity and, if so, for how long? How accurate is…
Test Performance | Government/Law | Policy/Regulation | Infectious Diseases | Probability/Bayes | Technology Assessment | Health Systems | Health/Medicine | Global | North America -
ArticlePublication 2019Cost-Effectiveness of Latent TB Screening before Immigration to Low-Incidence Countries
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening …
Despite prospective migrants to countries where the incidence of TB is low receiving TB screening for active infections, screening for latent TB infection before immigration is rare. The authors used discrete event simulation to evaluate the cost-effectiveness preimmigration latent TB infection screening for migrants to low-incidence countries. They calculated cost per quality-adjusted life-year gained for migrants from countries with different TB incidences. Their analysis when combined with research on sustainability, acceptability, and program implementation can…
Dynamic Simulation | Cost-Effectiveness Analysis | Government/Law | Infectious Diseases | Mathematical Models | Health/Medicine | Global -
ArticlePublication 2017When Cost-Effective Interventions Are Unaffordable
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, …
Many health interventions deemed cost-effective are not affordable. Despite the importance of affordability to policymakers, little of the cost-effectiveness literature in global health addresses this issue. Budget impact analysis (BIA) describes an intervention's short-term costs and savings from the payer's perspective. This paper assesses the current use of budget impact analysis (BIA) and cost-effectiveness analysis (CEA) in health economic assessments conducted for low- and middle-income countries (LMICs). The authors recommend steps researchers and policymakers can…
Cost-Effectiveness Analysis | Costing Methods | Government/Law | Infectious Diseases | Priority Setting/Ethics | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Science/Technology | Global -
ArticlePublication 2014Evaluation of FDA Benefit-Cost Analysis of Graphic Warning Labels
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing …
The Food and Drug Administration (FDA) is required to do a regulatory impact analysis assessing the costs and benefits of its tobacco products and other regulations. This paper provides a critical review of the approach the FDA used in its proposed and final graphic warning label rule, and includes recommendations on how to improve the analysis in ways that account for the differences between tobacco use and consumption of most consumer products. To date, FDA…
Benefit-Cost Analysis | Costing Methods | Government/Law | Policy/Regulation | Chronic Disease/Risk | Health/Medicine | North America -
ArticlePublication 2016What Determines HIV Prevention Costs at Scale?
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, …
Human immunodeficiency virus (HIV) prevention services for key populations are commonly delivered through NGOs. However, funding for HIV prevention remains scarce, and there are growing calls internationally to improve the efficiency of HIV prevention programmes as a key strategy to reach global HIV targets. To date, there is limited evidence on the determinants of costs of HIV prevention delivered through NGOs, and thus, policymakers have little guidance in how best to design programmes that are…
Cost-Effectiveness Analysis | Costing Methods | Government/Law | Infectious Diseases | Health Systems | Global Governance | Economics/Finance | Health/Medicine | Asia & Pacific -
ArticlePublication 2014Economic Implications of Population Ageing in China & India: Introduction to the Special Issue
In this special issue of The Journal of the Economics of Ageing, we focus on economic …
In this special issue of The Journal of the Economics of Ageing, we focus on economic aspects of population ageing in the world’s two population superpowers: China and India. China and India have been the subject of comparison for many years. Observations about their relative political and economic development abound (see for example Sen, 2013), but little analysis is currently available of their comparative demographic trajectories and the possible economic consequences of the population ageing that they are both undergoing. These demographic…
Costing Methods | Health Outcomes | Government/Law | Policy/Regulation | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Asia & Pacific -
ArticlePublication 2020Valuing COVID-19 Mortality Risk
In this article, the author evaluates whether conventional estimates of the value per statistical life …
In this article, the author evaluates whether conventional estimates of the value per statistical life (VSL) in the United States (about $10 million) are appropriate for evaluating policies that affect risk of COVID-19. This estimate may be too large, because: (1) VSL estimates marginal values but COVID-19 risks can be non-marginal; (2) VSL is estimated for the average resident, but COVID-19 mortality is concentrated among the elderly; and (3) the pandemic has caused substantial losses…
Benefit-Cost Analysis | Government/Law | Infectious Diseases | Preferences/Values | Global